FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2899735141> ?p ?o ?g. }

• W2899735141 abstract "Introduction: Inhibitors of sodium-glucose cotransporter-2 (SGLT-2) are proposed as a novel approach for the management of type 2 diabetes mellitus. SGLT-2 inhibitors have major advantages in terms of reducing HbA1c, blood sugar levels, body weight, and blood pressure and may potentially reduce the cardiovascular (CV) risk. The objective of the study is to assess the safety and efficacy of SGLT-2 inhibitors as an adjuvant to insulin add-on therapy in uncontrolled type 2 diabetic patients. Materials and Methods: The study was conducted in 100 patients with uncontrolled type 2 diabetes mellitus. 50 patients were received SGLT-2 inhibitor add-on therapy with gliclazide-metformin and insulin, and remaining 50 patients were received insulin add-on therapy with gliclazide metformin. The changes in fasting blood sugar (FBS), glycosylated hemoglobin (HbA1c), weight, body mass index (BMI), blood pressure, and CV risk of diabetic patients before the initiation of add-on therapy and after 6 months follow-up were measured. Diabetes-related complications such as foot ulcer, hypoglycemic episodes, and urinary tract infections were documented. Results: Patients on SGLT-2 inhibitors as adjuvant to insulin add-on therapy show better glycemic control, reduction in weight, BMI, blood pressure, and CV risk. In patients with SGLT-2 inhibitors add-on therapy, these were changes from baseline HbA1c (2.333%), FBS (82.97 mg/dL), and BMI (2.049 kg/m2). In hypertensive patients, mean reduction in systolic blood pressure (SBP) and diastolic blood pressure (DBP) was 15.12 mmHg and 6.40 mmHg, respectively. In non-hypertensive patients, mean reduction in SBP and DBP was 7.60 mmHg and 1.88 mmHg, respecively. The mean CV risk reduction was 6.046%. Among 50 patients, 3 developed urinary tract infection (UTI) and 1 developed hypoglycemia. In insulin add-on therapy patients, these were changes from baseline HbA1c, FBS, and BMI 1.029%, 39.98 mg/dL, and −1.584 kg/m2, respectively. In hypertensive patients, SBP was 10.84 mmHg and DBP was 4.120 mmHg, and in non-hypertensive patients, mean reduction in SBP and DBP was −3.080 mmHg and −3.36 mmHg. The mean CV risk reduction was 0.866%. Of 50 patients, 5 developed UTI, 9 developed hypoglycemia, and 3 developed foot ulcer. Conclusion: SGLT-2 inhibitors are safe and effective for treatment in uncontrolled T2DM. The use of SGLT-2 inhibitors is very effective in glycemic control (reduction in HbA1c and FBS). The non-glycemic effects of SGLT-2 inhibitors include reduction in weight, BMI, and blood pressure. Therefore, glycemic and non-glycemic benefits contribute to an overall reduction in CV risk." @default.
• W2899735141 created "2018-11-16" @default.
• W2899735141 creator A5070121288 @default.
• W2899735141 date "2018-09-01" @default.
• W2899735141 modified "2023-10-16" @default.
• W2899735141 doi "https://doi.org/10.22377/ajp.v12i03.2625" @default.
• W2899735141 hasPublicationYear "2018" @default.
• W2899735141 type Work @default.
• W2899735141 sameAs 2899735141 @default.
• W2899735141 citedByCount "0" @default.
• W2899735141 crossrefType "journal-issue" @default.
• W2899735141 hasAuthorship W2899735141A5070121288 @default.
• W2899735141 hasBestOaLocation W28997351411 @default.
• W2899735141 hasConcept C126322002 @default.
• W2899735141 hasConcept C134018914 @default.
• W2899735141 hasConcept C2777180221 @default.
• W2899735141 hasConcept C2777448766 @default.
• W2899735141 hasConcept C2779306644 @default.
• W2899735141 hasConcept C2780221984 @default.
• W2899735141 hasConcept C2780323712 @default.
• W2899735141 hasConcept C2780473172 @default.
• W2899735141 hasConcept C2910068830 @default.
• W2899735141 hasConcept C555293320 @default.
• W2899735141 hasConcept C71924100 @default.
• W2899735141 hasConcept C84393581 @default.
• W2899735141 hasConcept C90924648 @default.
• W2899735141 hasConceptScore W2899735141C126322002 @default.
• W2899735141 hasConceptScore W2899735141C134018914 @default.
• W2899735141 hasConceptScore W2899735141C2777180221 @default.
• W2899735141 hasConceptScore W2899735141C2777448766 @default.
• W2899735141 hasConceptScore W2899735141C2779306644 @default.
• W2899735141 hasConceptScore W2899735141C2780221984 @default.
• W2899735141 hasConceptScore W2899735141C2780323712 @default.
• W2899735141 hasConceptScore W2899735141C2780473172 @default.
• W2899735141 hasConceptScore W2899735141C2910068830 @default.
• W2899735141 hasConceptScore W2899735141C555293320 @default.
• W2899735141 hasConceptScore W2899735141C71924100 @default.
• W2899735141 hasConceptScore W2899735141C84393581 @default.
• W2899735141 hasConceptScore W2899735141C90924648 @default.
• W2899735141 hasLocation W28997351411 @default.
• W2899735141 hasOpenAccess W2899735141 @default.
• W2899735141 hasPrimaryLocation W28997351411 @default.
• W2899735141 hasRelatedWork W1595728277 @default.
• W2899735141 hasRelatedWork W2050769289 @default.
• W2899735141 hasRelatedWork W2118324484 @default.
• W2899735141 hasRelatedWork W2173431636 @default.
• W2899735141 hasRelatedWork W2562215606 @default.
• W2899735141 hasRelatedWork W3016463962 @default.
• W2899735141 hasRelatedWork W3134248779 @default.
• W2899735141 hasRelatedWork W4282921400 @default.
• W2899735141 hasRelatedWork W1574622010 @default.
• W2899735141 hasRelatedWork W3082637587 @default.
• W2899735141 isParatext "false" @default.
• W2899735141 isRetracted "false" @default.
• W2899735141 magId "2899735141" @default.
• W2899735141 workType "paratext" @default.